Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 28, 2022
Diagnostic Performance of Physician Gestalt for Bacteremia in Patients in the Process of Being Admitted With Suspected InfectionKotaro Fujii, Toshihiko Takada, Tsukasa Kamitani, et al.
Internal Medicine (Tokyo, Japan)|April 13, 2025
Efficacy and Safety of Rituximab plus Modified EPOCH (Etoposide, Vincristine, Doxorubicin, Carboplatin, and Prednisolone) for Transplant-ineligible Relapsed/Refractory Diffuse Large B-cell LymphomaEriko Fujioka, Junichi Kiyasu, Ilseung Choi, et al.
Annals of Hematology|April 28, 2023
Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphomaYu Yagi, Yusuke Kanemasa, Yuki Sasaki, et al.
Ejhaem|August 21, 2023
Hemoglobin-platelet index as a prognostic factor in patients with peripheral T-cell lymphomaYu Yagi, Yusuke Kanemasa, Yuki Sasaki, et al.
International Cancer Conference Journal|October 14, 2024
Management of HER2-positive and microsatellite instability-high advanced gastric cancer: a case reportTaichi Tamura, Yusuke Kanemasa, Shohei Nakamura, et al.
International Cancer Conference Journal|January 27, 2026
Concurrent tumor lysis syndrome and 5-fluorouracil encephalopathy during the first cycle of zolbetuximab plus mFOLFOX6 for CLDN18.2-positive gastric cancer: a case reportTaichi Tamura, Yusuke Kanemasa, Yusuke Masuda, et al.
Medicine|December 6, 2021
Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case reportYu Yagi, Yusuke Kanemasa, An Ohigashi, et al.
European Journal of Haematology|May 27, 2025
Site- and Stage-Adapted Treatment Strategies for Gastrointestinal Diffuse Large B-Cell LymphomaYu Yagi, Yusuke Kanemasa, Yuki Sasaki, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 6, 2023
[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant]Yuka Morita, Yu Yagi, Yusuke Kanemasa, et al.
Cancer Medicine|August 28, 2023
Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective studyYu Yagi, Yusuke Kanemasa, Yuki Sasaki, et al.
Pageof 3